Mr. Rashid Ahmed reports

BIOMARK RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA

Biomark Diagnostics Inc. has received a no objection letter (NOL) to extend its trials in both Canada and Bangladesh from Health Canada's Office of Clinical Trials.

Rashid Ahmed, president and chief executive officer, commented: "This marks another milestone for Biomark and allows the company to gather more representative data for analytical purposes, especially for the types of cancers that Biomark is currently building its diagnostics and screening applications and platform for. Following Health Canada clearance, the extended trials will allow Biomark to gather more data, which can potentially allow Biomark to demonstrate the efficacy of its cancer diagnostic tests that we believe has significant medical, patient and commercial opportunity."

We seek Safe Harbor.